samedan logo

 
 
spacer
home > pmps > spring 2019 > the importance of product master data
PUBLICATIONS
Pharmaceutical Manufacturing and Packing Sourcer

The Importance of Product Master Data

By November 2019, wholesale distributors will be required to verify the serialised product identifiers for any saleable products that have been returned to them before they can be restocked and resold. With this new saleable returns verification requirement, the challenges of master data exchange for manufacturers will come to the fore.

To manage the scope, scale, and challenges of the saleable returns requirement, wholesalers and manufacturers must re-evaluate their current methods of exchanging product master data information.

The Scale of the Challenge

The national organisation representing primary wholesale distributors in the US, the Healthcare Distribution Alliance (HDA), executed analysis of saleable returns. This showed that approximately 60 million units of drug product are returned annually, with the majority of saleable returns caused by overstocking (1).

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
Dan Walles is the General Manager of Track & Trace and Compliance at TraceLink, where he brings more than 20 years of experience in product management, solution consulting, and service delivery to his role. He has focused exclusively on the needs of the life sciences industry for the past 15 years. Since joining TraceLink in 2010, Dan has been instrumental in educating customers on TraceLink’s Life Sciences Cloud and partner ecosystem to enable compliance and added business value through supply chain visibility and improved patient outcomes.
spacer
Dan Walles
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

uMotif Announces First New Validated Innovation in eCOA/ePRO Since Paper Instruments Were Deployed on Smartphones

Patent-protected Motif data capture interface proven as equivalent method to capture Patient Reported Outcome and eDiary data, eliminates reliance on text-based instruments, in study with 55 participants in 2 randomized groups conducted by SAFIRA Clinical Research at Dublin City University
More info >>

White Papers

Six Strategies to Stretch Your Limited Drug Supply for Clinical Studies

PCI Pharma Services

Bringing a new drug to market can be a heavy financial burden on any pharmaceutical company. It has become even more burdensome over the last several years as the industry pushes the boundaries of innovation. This is because newer, often more-complex therapies not only increase risk in drug development but also drive costs even higher. A recent analysis of the investment needed to develop a new prescription medicine shows the total cost can be as high as $2.6 billion (1). That number becomes even more staggering when you consider the fact that only about 12 percent of drug candidates that make it to Phase I testing are eventually approved by the FDA (2). The investment companies lose as a result may be too devastating to their bottom line to ever recover.
More info >>

 

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement